The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

Valneva press release (NASDAQ ... product tech transfers to Valneva’s brand-new state-of the art facility in Scotland. Other income is now expected between €100 million and €110 million ...

Gregor Poynton was speaking after it was revealed £4 million has already been invested in key projects in the constituency, ...

UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci ...

Livingston-based Valneva Scotland bagged a brace of awards at a glittering ceremony in Glasgow. The company won several awards at Scotland’s annual Life Sciences Awards 2024, including the award ...

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), allowing the single-dose vaccine to be made available for adults ...

The news is a timely boost for Paris, France-based Valneva, which is facing uncertain ... are ongoing to supply 25,000 doses to the NHS in Scotland. Starting phase 3 testing of VLA15 will trigger ...

In a report released on January 31, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva (0OB3 – Research Report), with a price target of €8.10. The company’s shares closed ...

The vaccine is manufactured at Valneva’s leading vaccine production site in Livingston, Scotland. The approval is based on IXCHIQ ® ’s final pivotal Phase 3 data, published in The Lancet ...